What does CJC-1295 with DAC do? Benefits and evidence

An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.

Also called: CJC-1295 DAC, DAC:GRF, DAC-GRF.

GHRH analogues · Long-acting GHRH receptor agonist with an albumin-binding tag.

CJC-1295 with DAC is an experimental injection that raises growth hormone and IGF-1 for days. Small human studies measured hormones, not muscle gain, recovery or longevity. An HIV trial stopped early and has no published results. Flushing, headaches and injection reactions were frequent. It has no FDA approval.

  • In small studies, one shot raised growth hormone and IGF-1 for days; muscle gain and recovery were not tested. (Studied in a trial)
  • With weekly or every-other-week shots, IGF-1 levels stayed raised in a small study. (Studied in a trial)
  • People report using it for muscle, body shape, skin, sleep and injury recovery. (Reported by users)
  • Individual users report better mood, energy, strength or endurance; this does not show the drug caused it. (Reported by users)

Uses in the sources

  • Studied for GH and IGF-1 release in healthy adults; a terminated HIV visceral-fat study has no posted results. (Studied in a trial) (source)
  • People report use for muscle and body composition. Controlled trials have not established these benefits. (Reported by users) (source)
  • Reported for exercise and injury recovery; hormone increases do not establish faster healing. (Reported by users) (source)
  • Sleep improvement is a reported reason for use, not an established treatment effect. (Reported by users) (source)

Related to CJC-1295 with DAC

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.